Jefferies Global Healthcare Conference
Avacta CEO and CFO to attend Jefferies Global Healthcare Conference for investor meetings.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON and PHILADELPHIA – November 2, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces that Christina Coughlin, CEO and Brian Hahn, CFO will be attending the Jefferies Global Healthcare Conference and hosting one-on-one meeting with investors. The conference is taking place in London from November 16-19, 2026.
Interested parties are invited to contact Avacta via the conference partnering system to arrange a one-on-one meeting during the event.
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre | CISION® platform. pre | CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre | CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. |
| Our pre | CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre | CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. |
About FAP-Exd (AVA6103)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.